Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>

Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2021-11-18 Purchase | 2021-11-22 07:30 am | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 1,430 | $35.09 | $50,181 | 426,528 (Indirect Direct) | View |
2021-05-12 Purchase | 2021-05-13 07:05 am | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 500 | $58.15 | $29,075 | 425,098 (Indirect Direct) | View |
2020-06-29 Purchase | 2020-06-30 08:20 am | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 650 | $78.5 | $51,025 | 408,798 (Indirect Direct) | View |
2019-06-25 Purchase | 2019-06-27 07:18 am | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 16,200 | $23.1 | $374,280 | 673,948 (Indirect Direct) | View |
2019-05-13 Purchase | 2019-05-15 07:21 am | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 4,650 | $21.44 | $99,696 | 657,748 (Indirect Direct) | View |
2019-03-19 Purchase | 2019-03-21 07:05 am | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 5,100 | $12.18 | $62,118 | 653,098 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2023-03-02 Option Award | 2023-03-06 6:13 pm | 2023-03-02 2033-03-01 | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 2,870 | $0 | 2,870 (Direct) | View |
2023-01-03 Exercise | 2023-01-04 4:11 pm | 2013-03-22 2023-03-21 | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 17,501 | $0 | 447,525 (Direct) | View |
2023-01-03 Exercise | 2023-01-04 4:11 pm | N/A N/A | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 17,501 | $1.3 | 447,525 (Direct) | View |
2022-06-03 Option Award | 2022-06-07 4:07 pm | 2023-06-03 2032-06-03 | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 16,976 | $0 | 16,976 (Direct) | View |
2022-03-15 Exercise | 2022-03-17 07:05 am | 2013-03-22 2023-03-21 | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 3,496 | $0 | 447,525 (Direct) | View |
2022-03-15 Exercise | 2022-03-17 07:05 am | N/A N/A | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 3,496 | $1.3 | 447,525 (Direct) | View |
2022-03-04 Option Award | 2022-03-08 5:00 pm | 2022-03-04 2032-03-03 | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 2,798 | $0 | 2,798 (Direct) | View |
2021-06-04 Option Award | 2021-06-08 4:51 pm | 2022-06-04 2031-06-04 | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 7,325 | $0 | 7,325 (Direct) | View |
2021-03-05 Option Award | 2021-03-09 9:45 pm | 2021-03-05 2031-03-04 | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 1,201 | $0 | 1,201 (Direct) | View |
2020-08-19 Gift | 2020-08-20 8:43 pm | N/A N/A | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 397,998 | $0 | 408,798 (Direct) | View |
2020-06-05 Option Award | 2020-06-05 6:40 pm | 2021-06-05 2030-06-05 | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 13,000 | $0 | 13,000 (Direct) | View |
2020-03-17 Option Award | 2020-03-19 9:17 pm | 2020-03-17 2030-03-16 | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 3,308 | $0 | 3,308 (Direct) | View |
2019-06-07 Option Award | 2019-06-10 6:20 pm | 2020-06-07 2029-06-07 | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 13,000 | $0 | 13,000 (Direct) | View |
2019-03-19 Option Award | 2019-03-21 4:06 pm | 2019-03-19 2029-03-18 | Axsome Therapeutics Inc. | AXSM | Coleman Mark Director | 25,652 | $0 | 25,652 (Direct) | View |